Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01166126
Recruitment Status : Terminated
First Posted : July 20, 2010
Results First Posted : May 23, 2013
Last Update Posted : May 15, 2014
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Tracking Information
First Submitted Date  ICMJE July 12, 2010
First Posted Date  ICMJE July 20, 2010
Results First Submitted Date March 29, 2013
Results First Posted Date May 23, 2013
Last Update Posted Date May 15, 2014
Study Start Date  ICMJE October 2010
Actual Primary Completion Date June 2012   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 23, 2013)
  • Number of Participants With Complete Response (CR) and Partial Response (PR) [ Time Frame: 1 year ]
    Anti-tumor response (CR+PR) was defined by Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
  • Number of Participants With Overall Survival (OS) at One Year [ Time Frame: 1 year post last treatment ]
    The one-year overall survival of the combination of temsirolimus and AZD6244 Hydrogen Sulfate.
Original Primary Outcome Measures  ICMJE
 (submitted: July 19, 2010)
Anti-tumor response rates and one-year overall survival rate. [ Time Frame: Average of 12 Months ]
The primary endpoint of this phase II study is anti-tumor response rates (CR+PR) by RECISTand one-year overall survival.
Change History Complete list of historical versions of study NCT01166126 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: March 29, 2013)
  • Number of Participants With Progression Free Survival (PFS) at 6 Months. [ Time Frame: 6 months from day 1 of treatment ]
    Patients will be evaluated by physical examination and imaging assessments (brain MRI and CT scans of the chest, abdomen and pelvis). Disease progression will be defined by RECIST criteria on physical exam or diagnostic imaging assessments that are attributed to metastatic melanoma. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
  • Number of Participants With Related Serious Adverse Events (SAEs) [ Time Frame: 1 year ]
    Toxicities assessed using NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0.
Original Secondary Outcome Measures  ICMJE
 (submitted: July 19, 2010)
  • Six month progression-free survival rate [ Time Frame: Average of 6 months ]
  • Progression-free survival rate. [ Time Frame: Average of 12 Months ]
  • Number of participants with adverse events [ Time Frame: Average of 12 Months ]
Current Other Outcome Measures  ICMJE Not Provided
Original Other Outcome Measures  ICMJE Not Provided
 
Descriptive Information
Brief Title  ICMJE Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
Official Title  ICMJE Phase II Trial of mTOR Inhibitor Temsirolimus Combined With MEK Inhibitor AZD 6244 in Patients With BRAF Mutant Stage IV Melanoma
Brief Summary The purpose of this study is to find out how often two investigational drugs that are given together will shrink the patient's tumor and how well they will prolong the time it takes their tumor to grow. The investigators also wish to find out how they affect certain substances in the patient's tumor and in their blood important for tumor growth. The combination of these drugs is experimental, and has not been proven to help treat melanoma
Detailed Description

PRIMARY OBJECTIVES:

I. To determine the clinical response rate (Response Evaluation Criteria in Solid Tumors [RECIST]) and one-year overall survival to the study drugs temsirolimus and AZD6244 (selumetinib) hydrogen sulfate in BRAF V600E mutant unresectable stage IV melanoma.

SECONDARY OBJECTIVES:

I. Estimate 6-month progression-free survival in patients receiving temsirolimus and AZD6244 hydrogen sulfate.

II. Determine the pharmacodynamic effects of temsirolimus and AZD6244 on pERK, s6K, PTEN and mediators of apoptosis.

III. Determine the toxicity profile of temsirolimus with AZD6244 hydrogen sulfate.

OUTLINE:

Treatment Phase: This period begins with the first intravenous (through the vein) infusion of TEMSIROLIMUS and the first AZD6244 administration by mouth (visit 2, Week 1) and will continue until Week 8 (Visit 4).

As many as 38 patients will receive the same dosage of TEMSIROLIMUS injected in the veins once a week for 8 weeks, and the AZD6244 will be given as capsules by mouth twice a day for 8 weeks. That is one cycle. The TEMSIROLIMUS and AZD6244 will be given to participants as an outpatient, unless admission to the hospital was needed for treatment of related side effects or underlying disease. The subsequent cycles of TEMSIROLIMUS and AZD6244 will be given every 8 weeks. The TEMSIROLIMUS will be injected in a vein over 30 minutes.

The continuation phase begins with visits at weeks 12 in patients who receive at least two cycles of treatments.

Study Type  ICMJE Interventional
Study Phase Phase 2
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Mucosal Melanoma
  • Recurrent Melanoma
  • Stage IV Melanoma
Intervention  ICMJE
  • Drug: temsirolimus
    Given IV
    Other Names:
    • CCI-779
    • cell cycle inhibitor 779
    • Torisel
  • Drug: selumetinib
    Given orally
    Other Names:
    • ARRY-142886
    • AZD6244
  • Other: laboratory biomarker analysis
    Correlative studies
Study Arms Experimental: Treatment (temsirolimus and selumetinib)

Treatment Phase: This period begins with the first intravenous (through the vein) infusion of TEMSIROLIMUS and the first AZD6244 administration by mouth (visit 2, Week 1) and will continue until Week 8 (Visit 4).

As many as 38 patients will receive the same dosage of TEMSIROLIMUS injected in the veins once a week for 8 weeks, and the AZD6244 will be given as capsules by mouth twice a day for 8 weeks. That is one cycle. The TEMSIROLIMUS and AZD6244 will be given to participants as an outpatient, unless admission to the hospital was needed for treatment of related side effects or underlying disease. The subsequent cycles of TEMSIROLIMUS and AZD6244 will be given every 8 weeks. The TEMSIROLIMUS will be injected in a vein over 30 minutes.

The continuation phase begins with visits at weeks 12 in patients who receive at least two cycles of treatments.

Interventions:
  • Drug: temsirolimus
  • Drug: selumetinib
  • Other: laboratory biomarker analysis
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: April 29, 2014)
4
Original Estimated Enrollment  ICMJE
 (submitted: July 19, 2010)
38
Actual Study Completion Date June 2012
Actual Primary Completion Date June 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subject must have read, understood, and provided written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization after the nature of the study has been fully explained
  • Subjects with a histologic diagnosis of unresectable stage IV melanoma (may include mucosal melanoma)
  • Tumor must be BRAF V600E mutation positive from a certified lab
  • At least 4 weeks since any previous treatment (surgery, radiotherapy, or systemic treatment)
  • Women should be either: post-menopausal for at least 1 year; surgically incapable of bearing children; or utilizing a reliable form of contraception during the study and for at least 4 months after the final study drug infusion or ingestion; women of childbearing potential must have a negative serum hCG-beta pregnancy test conducted during the screening period
  • Men who may father a child must agree to the use of male contraception for the duration of their participation in the trial and for at least 4 months after the final temsirolimus and AZD6244 hydrogen sulfate administration
  • Life expectancy >= 3 months
  • ECOG performance status of 0 or 1
  • Patients with brain metastases treated with surgery, radiation, or stereotactic radiosurgery who are without evidence of progression in their brain metastases after MRI imaging performed at least 30 days after treatment, and are not taking systemic steroids will be eligible
  • WBC >= 3000 cells/mm^3
  • ANC >= 1500 cells/mm^3
  • Platelets >= 100,000/mm^3
  • Hematocrit >= 30%
  • Hemoglobin >= 9 g/dL
  • Creatinine =< 2.0 mg/dL
  • AST/ALT =< 2 x ULN
  • Bilirubin =< 1.5 x ULN, (except subjects with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dL)
  • HIV negative
  • HBsAg negative
  • Anti-HCV Ab nonreactive; if reactive, subject must have a negative HCV RNA qualitative PCR
  • Patients with hyperlipidemia must have adequate control with a lipid lowering agent

Exclusion Criteria:

  • Any prior malignancy except for the following: adequately treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or any other cancer from which the subject has been disease-free for at least 5 years
  • Active infection, requiring therapy, chronic active HBV or HCV; patients with HIV, who have adequate CD4 counts and who do not require HAART therapy, are NOT excluded
  • Pregnancy or nursing: due to the possibility that temsirolimus and AZD6244 hydrogen sulfate could have a detrimental effect on the developing fetus or infant, exposure in utero or via breast milk will not be allowed
  • Any underlying medical condition which, in the opinion of the principal investigator, will make the administration of study drug hazardous or obscure the interpretation of adverse events
  • Prior treatment with temsirolimus or AZD6244 or any prior mTOR or MEK inhibitor
  • Evidence or history of significant cardiac, pulmonary, hepatic, renal, psychiatric or gastrointestinal disease that would make the administration of temsirolimus or AZD6244 hydrogen sulfate unsafe
  • Tumor that is BRAF V600E mutation negative
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01166126
Other Study ID Numbers  ICMJE NCI-2012-02846
NCI-2012-02846 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
MCC-16066 ( Other Identifier: H. Lee Moffitt Cancer Center and Research Institute )
8436 ( Other Identifier: CTEP )
P30CA076292 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party National Cancer Institute (NCI)
Study Sponsor  ICMJE National Cancer Institute (NCI)
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Ragini Kudchadkar H. Lee Moffitt Cancer Center and Research Institute
PRS Account National Cancer Institute (NCI)
Verification Date December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP